Northwest Bank provides $34.5 million loan for Luzern Associates' $47.75 million Cherry Hill industrial portfolio acquisition
Bitget2026/10/06 12:08Northwest Bancshares’ Northwest Bank provided USD 34.5 million financing for Luzern Associates’ USD 47.75 million Cherry Hill industrial portfolio acquisition. Deal covers a three-building campus in Danvers, Massachusetts totaling nearly 200,000 square feet. Medtronic occupies about 70% of the portfolio’s square footage; properties are fully occupied. Loan structured as commercial real estate financing; remaining purchase price funded with equity from a strategic investor. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Bancshares Inc. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Northwest Bancshares’ Northwest Bank provided USD 34.5 million financing for Luzern Associates’ USD 47.75 million Cherry Hill industrial portfolio acquisition.
- Deal covers a three-building campus in Danvers, Massachusetts totaling nearly 200,000 square feet.
- Medtronic occupies about 70% of the portfolio’s square footage; properties are fully occupied.
- Loan structured as commercial real estate financing; remaining purchase price funded with equity from a strategic investor.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.